Retrospective Review of Amino Acid Formula Use at a Children's Center

November 18, 2019 updated by: Nestlé
This is a retrospective review of data documented in medical records.

Study Overview

Detailed Description

This is a retrospective review of data documented in medical records of patients consuming an amino-acid based enteral formula at a pediatric care facility in the United States.

Study Type

Observational

Enrollment (Actual)

23

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73008
        • Children's Center for Rehabilitation Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The population studied retrospectively will be children in a pediatric feeding center consuming an amino acid-based enteral fomula and meeting the inclusion/ exclusion criteria.

Description

Inclusion Criteria:

  • Consuming or with a history of consuming an amino acid-based formula

Exclusion Criteria:

  • Medical records lacking information on consumption of an amino acid-based formula

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Enteral Tube fed children
Enteral Formula
Enteral Feeding with an amino acid-based formula

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Documented indication for formula use
Time Frame: Up to 12 months before formula switch
Medical diagnosis
Up to 12 months before formula switch

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body weight
Time Frame: 12, 6 months prior to formula switch, at formula switch, and 6, 12 months post switch
Body weight in kilograms
12, 6 months prior to formula switch, at formula switch, and 6, 12 months post switch
Length/height
Time Frame: 12, 6 months prior to formula switch, at formula switch, and 6, 12 months post switch
Length or height (based on age) in centimeters
12, 6 months prior to formula switch, at formula switch, and 6, 12 months post switch
Formula volume consumption
Time Frame: 12, 6 months prior to formula switch, at formula switch, and 6, 12 months post switch
Average of 7 days
12, 6 months prior to formula switch, at formula switch, and 6, 12 months post switch
Stool frequency
Time Frame: 12, 6 months prior to formula switch, at formula switch, and 6, 12 months post switch
Average of 7 days
12, 6 months prior to formula switch, at formula switch, and 6, 12 months post switch
Stool consistency
Time Frame: 12, 6 months prior to formula switch, at formula switch, and 6, 12 months post switch
Average of 7 days
12, 6 months prior to formula switch, at formula switch, and 6, 12 months post switch
Vomiting
Time Frame: 12, 6 months prior to formula switch, at formula switch, and 6, 12 months post switch
Average of 7 days
12, 6 months prior to formula switch, at formula switch, and 6, 12 months post switch

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 15, 2018

Primary Completion (Actual)

December 31, 2018

Study Completion (Actual)

January 31, 2019

Study Registration Dates

First Submitted

April 5, 2018

First Submitted That Met QC Criteria

April 5, 2018

First Posted (Actual)

April 13, 2018

Study Record Updates

Last Update Posted (Actual)

November 19, 2019

Last Update Submitted That Met QC Criteria

November 18, 2019

Last Verified

November 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • 17.10.US.HCN

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Enteral Feeding Intolerance

Clinical Trials on Enteral Formula

3
Subscribe